MicroRNA: Important Player in the Pathobiology of Multiple Myeloma

Recent studies have revealed a pivotal role played by a class of small, noncoding RNAs, microRNA (miRNA), in multiple myeloma (MM), a plasma cell (PC) malignancy causing significant morbidity and mortality. Deregulated miRNA expression in patient's PCs and plasma has been associated with tumor progression, molecular subtypes, clinical staging, prognosis, and drug response in MM. A number of important oncogenic and tumor suppressor miRNAs have been discovered to regulate important genes and pathways such as p53 and IL6-JAK-STAT signaling. miRNAs may also form complex regulatory circuitry with genetic and epigenetic machineries, the deregulation of which could lead to malignant transformation and progression. The translational potential of miRNAs in the clinic is being increasingly recognized that they could represent novel biomarkers and therapeutic targets. This review comprehensively summarizes current progress in delineating the roles of miRNAs in MM pathobiology and management.

• Publication year

  2014

• Venue

  BioMed Research International

• Publication date

  2014-06-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1155/2014/521586PMID 24991558PMCID 4065722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In Vivo Activity of MiR-34a Mimics Delivered by Stable Nucleic Acid Lipid Particles (SNALPs) against Multiple Myeloma

  2014cited by this paper
• IMWG consensus on risk stratification in multiple myeloma

  2014cited by this paper
• Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance

  2014cited by this paper
• In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma

  2013cited by this paper
• Epigenetic inactivation of the MIR129-2 in hematological malignancies

  2013cited by this paper
• BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

  2013cited by this paper
• Molecular pathogenesis of multiple myeloma: basic and clinical updates

  2013cited by this paper
• Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia

  2013influential reference
• Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth

  2013influential reference
• Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype

  2013influential reference
• Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication

  2013cited by this paper
• Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression

  2013cited by this paper
• Myeloma: classification and risk assessment.

  2013influential reference
• miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells

  2013influential reference
• Improved risk stratification in myeloma using a microRNA‐based classifier

  2013influential reference
• miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease

  2013cited by this paper
• miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.

  2013cited by this paper
• Serum miR-29a as a marker of multiple myeloma

  2013cited by this paper
• Tumor‐suppressive microRNA silenced by tumor‐specific DNA hypermethylation in cancer cells

  2012cited by this paper
• Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders

  2012cited by this paper
• Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma

  2012cited by this paper
• Impact of MiRSNPs on Survival and Progression in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

  2012cited by this paper
• Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma

  2012cited by this paper
• Targeted therapy of multiple myeloma

  2012cited by this paper
• Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics.

  2012influential reference
• miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1

  2012influential reference
• MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma.

  2012influential reference
• Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence

  2012cited by this paper
• DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma

  2012influential reference
• Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.

  2012cited by this paper
• Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells

  2011cited by this paper
• Down-regulated miR-331–5p and miR-27a are associated with chemotherapy resistance and relapse in leukaemia

  2011cited by this paper
• Plasma cell leukemia.

  2011cited by this paper
• Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma.

  2011cited by this paper
• Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma.

  2011cited by this paper
• MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC

  2011influential reference
• Dysregulation of microRNAs in cancer: Playing with fire

  2011cited by this paper
• MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival

  2011influential reference
• Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma

  2011cited by this paper
• MicroRNAs and epigenetics

  2011cited by this paper
• Epigenetic silencing of MIR203 in multiple myeloma

  2011cited by this paper
• Role for MicroRNAs in Regulating Glucocorticoid Response and Resistance in Multiple Myeloma

  2011cited by this paper
• MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways

  2011influential reference
• Pancreatic cancer: understanding and overcoming chemoresistance

  2011influential reference
• Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1.

  2011cited by this paper
• Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

  2011cited by this paper
• miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma.

  2011influential reference
• Epigenetic inactivation of the MIR34B/C in multiple myeloma.

  2011cited by this paper
• Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation

  2011influential reference
• Epigenetic inactivation of the miR-34a in hematological malignancies.

  2010cited by this paper
• Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

  2010cited by this paper
• MicroRNA Profiles of Drug-Resistant Myeloma Cell Lines

  2010cited by this paper
• MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential.

  2010cited by this paper
• Negative Regulation of the Tumor Suppressor p53 Gene by MicroRNAs

  2010influential reference
• miRBase: integrating microRNA annotation and deep-sequencing data

  2010cited by this paper
• Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

  2010cited by this paper
• The widespread regulation of microRNA biogenesis, function and decay

  2010cited by this paper
• Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling

  2010influential reference
• MicroRNA control of signal transduction

  2010cited by this paper
• Multiple myeloma - current issues and controversies.

  2010cited by this paper
• High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2

  2010influential reference
• Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma.

  2010cited by this paper
• Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

  2010cited by this paper
• Molecular Genetics of Multiple Myeloma

  2010cited by this paper
• Epigenetic Inactivation of the miR-124-1 in Haematological Malignancies

  2010cited by this paper
• Biogenesis of small RNAs in animals

  2009cited by this paper
• Dicer1 functions as a haploinsufficient tumor suppressor.

  2009cited by this paper
• Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context

  2009cited by this paper
• Multiple myeloma

  2009cited by this paper
• SnapShot: MicroRNAs in Cancer.

  2009cited by this paper
• MicroRNAs and cancer: short RNAs go a long way.

  2009cited by this paper
• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  2009cited by this paper
• TGFβR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma

  2009cited by this paper
• Integrative high‐resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles

  2009cited by this paper
• Epigenetic regulation of microRNA expression in colorectal cancer

  2009cited by this paper
• MicroRNAs in cancer: small molecules with a huge impact.

  2009cited by this paper
• Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.

  2009cited by this paper
• Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma.

  2009cited by this paper
• Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma

  2009cited by this paper
• MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

  2009influential reference
• MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis

  2008influential reference
• Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors

  2008cited by this paper
• An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma

  2008cited by this paper
• The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition.

  2008cited by this paper
• Clinical and biological significance of RAS mutations in multiple myeloma

  2008cited by this paper
• Genetic aberrations and survival in plasma cell leukemia

  2008cited by this paper
• Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

  2008cited by this paper
• Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels

  2007cited by this paper
• Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.

  2007cited by this paper
• Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.

  2007cited by this paper
• Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer.

  2007influential reference
• MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B

  2007cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007cited by this paper
• Genetic events in the pathogenesis of multiple myeloma.

  2007cited by this paper
• Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

  2007cited by this paper
• Tumour invasion and metastasis initiated by microRNA-10b in breast cancer

  2007cited by this paper
• Impaired microRNA processing enhances cellular transformation and tumorigenesis

  2007cited by this paper
• MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia

  2007cited by this paper
• A microRNA expression signature of human solid tumors defines cancer gene targets

  2006cited by this paper
• High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.

  2006cited by this paper

• Effect of Mechanical Environment Alterations in 3D Stem Cell Culture on the Therapeutic Potential of Extracellular Vesicles

  2025cites this paper
• Current updates regarding biogenesis, functions and dysregulation of microRNAs in cancer: Innovative approaches for detection using CRISPR/Cas13-based platforms (Review)

  2025cites this paper
• IGF2BP3 remodels the microRNA targeting landscape in MLL-AF4 leukemia

  2025cites this paper
• An Updated Review Summarizing the Pharmaceutical Efficacy of Genistein and its Nanoformulations in Ovarian Carcinoma.

  2024cites this paper
• Detection of new single nucleotide polymorphisms in plasma cells carcinoma (myeloma) by polymerase chain reaction–single strand conformation polymorphism and sequencing technical methods

  2024cites this paper
• Significance of extracellular vesicles in orchestration of immune responses in Mycobacterium tuberculosis infection

  2024cites this paper
• MicroRNA-mediated autophagy and drug resistance in cancer: mechanisms and therapeutic strategies

  2024cites this paper
• HKDC1 functions as a glucose sensor and promotes metabolic adaptation and cancer growth via interaction with PHB2

  2024cites this paper
• Exosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma

  2023cites this paper
• Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies

  2023cites this paper
• The Role of Hexokinase Domain Containing Protein-1 in Glucose Regulation During Pregnancy

  2021cites this paper
• Hexokinase domain-containing protein-1 in metabolic diseases and beyond.

  2021cites this paper
• MicroRNAs as a Potential New Preventive Approach in the Transition from Asymptomatic to Symptomatic Multiple Myeloma Disease

  2021cites this paper
• miRNAs Potentially Involved in Post Lung Transplant-Obliterative Bronchiolitis: The Role of miR-21-5p

  2021cites this paper
• Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?

  2020cites this paper
• Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma

  2020cites this paper
• Long non-coding RNA TUG1 knockdown hinders the tumorigenesis of multiple myeloma by regulating the microRNA-34a-5p/NOTCH1 signaling pathway

  2020cites this paper
• MiR-181a functions as an oncogene by regulating CCND1 in multiple myeloma

  2020cites this paper
• MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma.

  2020cites this paper
• Multiple Myeloma: Available Therapies and Causes of Drug Resistance

  2020cites this paper
• miR-489 suppresses multiple myeloma cells growth through inhibition of LDHA-mediated aerobic glycolysis

  2019cites this paper
• miR-221/222-Mediated Inhibition of Autophagy Promotes Dexamethasone Resistance in Multiple Myeloma.

  2019cites this paper
• MiR-19b and miR-20a suppress apoptosis, promote proliferation and induce tumorigenicity of multiple myeloma cells by targeting PTEN

  2019cites this paper
• MicroRNA-765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6.

  2019cites this paper
• STAT3: A Promising Therapeutic Target in Multiple Myeloma

  2019cites this paper
• The Biological Function and Clinical Significance of miR-886-5p in Multiple Myeloma

  2019cites this paper
• Pharmacodynamic Models of Differential Bortezomib Signaling Across Several Cell Lines of Multiple Myeloma

  2018cites this paper
• Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells

  2018cites this paper
• Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche

  2018cites this paper
• The expression and role of miR-181a in multiple myeloma

  2018cites this paper
• Identification specific miRNA in t(4;14) multiple myeloma based on miRNA‐mRNA expressing profile correlation analysis

  2018cites this paper
• Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment

  2017cites this paper
• Identification of a novel microRNA, miR-4449, as a potential blood based marker in multiple myeloma

  2017cites this paper
• Epigenetics in multiple myeloma: From mechanisms to therapy.

  2017cites this paper
• Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis

  2017cites this paper
• MicroRNA expression patterns and target prediction in multiple myeloma development and malignancy

  2017influential citation
• The miR-125a and miR-320c are potential tumor suppressor microRNAs epigenetically silenced by the polycomb repressive complex 2 in multiple myeloma

  2017cites this paper
• Decreased microRNA-181a and -16 expression levels in the labial salivary glands of Sjögren syndrome patients.

  2017cites this paper
• Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in berberine-induced multiple myeloma cells

  2017cites this paper
• Identification of miRSNPs associated with the risk of multiple myeloma

  2017influential citation
• Targeted Inhibition of Polycomb Repressive Complexes in Multiple Myeloma : Implications for Biology and Therapy

  2017cites this paper
• Microenvironment drug resistance in multiple myeloma: emerging new players

  2016cites this paper
• Comparison of Extracellular Vesicles isolation protocols from the plasma of patients with multiple myeloma: size characterization, expression of EV markers and microRNAs

  2016influential citation
• EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions

  2016cites this paper
• Multiple myeloma cells modify VEGF/IL‐6 levels and osteogenic potential of bone marrow stromal cells via Notch/miR‐223

  2016cites this paper
• Downregulation of MicroRNA-152 contributes to high expression of DKK1 in multiple myeloma

  2015cites this paper
• MicroRNA181a Is Overexpressed in T-Cell Leukemia/Lymphoma and Related to Chemoresistance

  2015cites this paper
• Epigenetic modifications as regulatory elements of autophagy in cancer.

  2015cites this paper
• Infrequent DNA methylation of miR-9-1 and miR-9-3 in multiple myeloma

  2015cites this paper
• Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma

  2015cites this paper
• HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer

  2015cites this paper
• MiR-301a promotes cell proliferation by directly targeting TIMP2 in multiple myeloma.

  2015cites this paper
• Epigenetic Pathways Regulating Bone Homeostasis: Potential Targeting for Intervention of Skeletal Disorders

  2014cites this paper
• Cereblon and Its Role in the Treatment of Multiple Myeloma by Lenalidomide or Pomalidomide

  2014cites this paper